Protalix BioTherapeutics (PLX) EBT Margin Growth (3y) (2013 - 2026)
Protalix BioTherapeutics (PLX) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -484.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 132.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 6,685.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -2,054.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8,006.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 9,980.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -9,922.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 31,363.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -5,319.00 |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | -3,159.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,159.00 |
| Mar 31, 2026 | 9,326.00 |
| Dec 31, 2025 | -382.00 |
| Sep 30, 2025 | 3,769.00 |
| Jun 30, 2025 | 6,516.00 |
| Mar 31, 2025 | -2,269.00 |
| Dec 31, 2024 | 14,249.00 |
| Sep 30, 2024 | 5,703.00 |
| Jun 30, 2024 | 16,003.00 |
| Mar 31, 2024 | -7,451.00 |
| Dec 31, 2023 | -21,373.00 |
| Sep 30, 2023 | 2,560.00 |
| Jun 30, 2023 | 9,420.00 |
| Mar 31, 2023 | -3,738.00 |
| Dec 31, 2022 | -3,805.00 |
| Sep 30, 2022 | 7.00 |
| Jun 30, 2022 | 231.00 |
| Mar 31, 2022 | 5,719.00 |
| Dec 31, 2021 | 43,209.00 |
| Sep 30, 2021 | 80,177.00 |